Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis

Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis

  Background: Adalimumab is approved for Rheumatoid Arthritis (RA). In 2021, A biosimilar (ABP501;Amgevita®) was licensed in Iraq. The current study aimed to ensure safety and Efficacy of Amgevita in RA Patients in Iraq. Patients and Methods: A Cross sectional Observational study Started on 69...

Full description

Saved in:
Bibliographic Details
Main Authors: Yasameen Abbas, Nabaa Ihsan, Asal Adnan, Marwa Moayad, Ali AlKazzaz, Avin Maroof, Ali Abdulrahman, Nazar Abdulateef, Mohammad AlOsami, Faiq Gorial, Mohammed Altahhan, Zahraa Almansi, Ali Alnoori
Format: Article
Language:English
Published: University of Baghdad/ Al-Kindy College of Medicine 2024-12-01
Series:مجله كليه طب الكندي
Subjects:
Rheumatoid arthritis
Biosimilar
Adalimumab
Online Access:https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/1476
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/1476

Similar Items